Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis Vaccines and Diagnostics is set to take over 49% stake in a vaccine manufacturing unit, Chiron Behring Vaccines, from its joint venture partner Aventis Pharma, an Indian subsidiary of Sanofi-Aventis, for $22.3m.
Subscribe to our email newsletter
Novartis Pharma and Aventis, who have been involved in legal dispute over rights of anti-rabies vaccine Rabipur, have agreed to settle their dispute following the transaction.
Until February 2009, Aventis’ Chiron Behring Vaccines manufactured Rabipur at its plant in Ankleshwar, in Gujarat, and Novartis Healthcare distributed in India, reported business-standard.com.
However, Novartis was against the renewal of a 10-year marketing licence.
After losing Rabipur rights, Shanta Biotech, Aventis Pharma’s arm, introduced group company Sanofi Pasteur’s brand Verorab in India.
Against this, Novartis filed a case in the Bombay High Court, citing Aventis is selling the drug on its own instead of through their joint venture.
Following the deal, Aventis has agreed to offer certain utilities and services at the Chiron Behring Vaccines Ankleshwar plant for three years on mutually agreed terms.